Avinger, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
March 16, 2023 at 01:35 am IST
Share
Avinger, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2022. For the fourth quarter, the company reported sales was USD 2 million compared to USD 2.4 million a year ago. Net loss was USD 4.18 million compared to USD 5 million a year ago. Basic loss per share from continuing operations was USD 0.7 compared to USD 1.26 a year ago. Diluted loss per share from continuing operations was USD 0.7 compared to USD 1.26 a year ago.
For the full year, sales was USD 8.27 million compared to USD 10.13 million a year ago. Net loss was USD 17.62 million compared to USD 17.41 million a year ago. Basic loss per share from continuing operations was USD 4.36 compared to USD 4.57 a year ago. Diluted loss per share from continuing operations was USD 4.36 compared to USD 4.57 a year ago.
Avinger, Inc. is a commercial-stage medical device company. The Company designs, manufactures, and sells real-time, image-guided, minimally invasive catheter-based systems that are used by physicians to treat patients with peripheral artery disease (PAD). Its Lumivascular platform includes the Lightbox real-time imaging console, the Ocelot and Tigereye family of catheters, which are image-guided catheters designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (CTO), and the Pantheris family of catheters, its image-guided atherectomy family of catheters designed to allow physicians to remove arterial plaque in PAD patients. Its Pantheris is a single-use product and provides physicians with the ability to see a cross-sectional view of the peripheral artery to guide the removal of blockages throughout the procedure. It has also developed a line extension of its Pantheris image-guided atherectomy platform, Pantheris Small Vessel (SV).
AVINGER, INC. 
